Showing results (251-260 of 319) with videos related to

Sort By:
Pageof 32
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2025
Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transferWeijie Du, Fatih Noyan, Oliver McCallion, et al.
Cell Reports. Medicine|June 4, 2025
Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cellsAnastasia Conti, Kety Giannetti, Federico Midena, et al.
Nature Communications|September 30, 2024
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cellsTobias Bexte, Nawid Albinger, Ahmad Al Ajami, et al.
Human Gene Therapy|August 3, 2026
Accelerating Translation of NK Cell Therapies to the Clinic: A European PerspectiveLea Rebecca Knapp, Katharina Sophie Fischer, Janika Sosat, et al.
Stem Cell Reports|October 13, 2015
Efficient Recombinase-Mediated Cassette Exchange in hPSCs to Study the Hepatocyte Lineage Reveals AAVS1 Locus-Mediated Transgene InhibitionLaura Ordovás, Ruben Boon, Mariaelena Pistoni, et al.
The New England Journal of Medicine|November 2, 2017
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyRichard S Finkel, Eugenio Mercuri, Basil T Darras, et al.
The Journal of Clinical Investigation|February 16, 2008
Proteomic identification of FHL1 as the protein mutated in human reducing body myopathyJoachim Schessl, Yaqun Zou, Meagan J McGrath, et al.
American Journal of Human Genetics|June 15, 2007
Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4Claudia Stendel, Andreas Roos, Tine Deconinck, et al.
Brain : a Journal of Neurology|December 7, 2007
Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patientsRudolf A Kley, Yorck Hellenbroich, Peter F M van der Ven, et al.
The Lancet. Neurology|December 23, 2021
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trialEugenio Mercuri, Nicolas Deconinck, Elena S Mazzone, et al.
Pageof 32